Navigation Links
Despite its Weak Pipeline, Schizophrenia Market May Benefit from Drugs Used in Similar Indications, Says GBI Research
Date:4/12/2016

LONDON, April 12, 2016 /PRNewswire/ --

A new report from business intelligence provider GBI Research - Frontier Pharma: Schizophrenia and Associated Indications - states that although the schizophrenia market is replete with unmet needs and its pipeline is paltry, the overall level of innovation for schizophrenia-related indications - which comprise depression, panic disorders, obsessive compulsive disorder, post-traumatic stress disorder and cognitive deficit - is far higher, and has the potential to provide some benefit to patients with schizophrenia.

The large population of schizophrenia patients in relation to its small pipeline of 134 products is indicative of a low level of investment in Research and Development (R&D), most likely due to a poor understanding of the underlying disease mechanisms. This acts as a strong barrier to the development of effective pharmaceutical products.

Managing Analyst Dominic Trewartha explains: "While current treatments offer some relief from symptoms such as hallucinations, they have not proven as effective for cognitive dysfunction and symptoms such as the inability to feel pleasure, and there are no disease-modifying drugs currently available. A number of combinations, such as the addition of adjuvant agents to antipsychotic medication, have been trialed, but they have had little impact."

GBI Research states that there are 360 products in the pipeline for conditions associated with schizophrenia, 60 of which are first-in-class, equating to 21% of products with a disclosed molecular target. Overall, while the proportion of first-in-class products is still low, there are more in the pipeline for schizophrenia-related indications, particularly depressions and cognitive deficit, than there are for schizophrenia itself, and these act across a far wider range of molecular targets.

Trewartha continues: "The range of innovation is relatively diverse in the pipelines for schizophrenia and related indications, with products acting on numerous novel molecular targets, including D-Amino Acid Oxidase, glutamate carboxypeptidase 2, and a number of probable G protein-coupled receptors.

"It is likely that small molecules will remain clinically and commercially the most successful molecule types across many therapy areas and indications, being particularly relevant in the central nervous system (CNS) and schizophrenia, with only limited prospects that new product approvals could change the landscape.

"Despite industry-wide trends towards a diversification in therapeutic molecule types, it is unlikely that this will be translated in CNS disorders and schizophrenia, due to the challenges of crossing the blood-brain barrier with larger and more complex molecular types."

Sample pages of GBI Research's report Frontier Pharma: Schizophrenia and Associated Indications are available upon request

About GBI Research 

GBI Research is a leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key healthcare industry influencers to ensure you stay up-to-date with the latest market trends. For more information about our offerings, please contact us on:

+44(0)161-359-5817 

Connect with GBI Research on social media for the latest healthcare market updates:

Facebook | LinkedIn | Twitter



'/>"/>
SOURCE GBI Research
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Despite the Numerous Agents in Development for the Treatment of Chronic HCV Infections, a Notable Share of Physicians in Europe Lack Awareness of the HCV Pipeline
2. ResearchMoz.us: Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
3. Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
4. Despite A Difficult Competitive Environment, Opportunities Can Still Be Found In The Growing US Trauma Fixation Device Market
5. Despite Increasing Cost Sensitivity of EU5 Payers, Sofosbuvir and Simeprevir are Poised to Reshape the Hepatitis C Virus Market by End of 2015
6. ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations
7. Power Morcellator Critic Vows to Carry On Despite Threat of Legal Action, Bernstein Liebhard LLP Reports
8. Despite Its Limited Size, Chiles Pharmaceutical Market Offers Growing Opportunity for Drug Industry
9. Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches
10. Asia-Pacific Rheumatoid Arthritis Therapeutics Markets 2015-2021 - Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs
11. Despite Push for Transparent Medical Records, 53% of Consumers Cant Access Electronic Health Data, HealthMine Survey Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)... , Sept. 8, 2017 Dealmed Medical Supplies, ... supplier of medical equipment, supplies, drugs, vaccines, and specialty ... entered into an agreement to acquire Vantage Medical Supplies, ... in Holtsville, New York . ... supplying new and emerging medical practices, will operate under ...
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), the company commercializing ... Pharma AG to distribute NuvoAir,s spirometry technology to physicians worldwide. ... platform and Novartis, commitment to address the unmet medical needs ... ... "We are ...
(Date:9/6/2017)... , Sept. 6, 2017   PDI , a ... it will host an educational session focused on the ... infection (CLABSI) prevention at the 2017 Annual Scientific Meeting ... will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... September 19, 2017 , ... CTNext , Connecticut’s ... Awards (EIA), held this past Thursday night at The Space in Hamden. ... their innovative project ideas to a panel of judges for an opportunity to ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... rallying cry to Americans to watch for the discomforts and hidden dangers of ... to senior citizens, everyone is at risk for developing fungal infections on the ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... unveiled the MirixaPro 6.0 platform. As the industry’s leading Medication Therapy Management ... delivered. Based on industry research and market feedback, the latest version of ...
(Date:9/19/2017)... Philadelphia, PA (PRWEB) , ... September 19, 2017 ... ... high-quality orthopedic dog beds, has been officially recognized for its September 2016 donation ... , The company recently received three awards and honors for its contribution ...
(Date:9/19/2017)... ... ... Public outrage over the toxins that exist in tap water and the lack ... itself to research, develop and ultimately supply consumers with healthy drinking water alternatives. Vitev ... alkaline water technologies, water filtration systems, and consumer education. , ...
Breaking Medicine News(10 mins):